Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioFocus Piles Up Data On HeartLight Laser AF Ablation Catheter

This article was originally published in The Gray Sheet

Executive Summary

In addition to the more than 1,300 ablation procedures completed outside the U.S. with the unique visually guided ablation catheter, the venture-backed company is conducting an IDE trial in 21 U.S. centers, which it expects to complete in 2014.

You may also be interested in...



Research Briefs: CardioFocus Trial Enrollment; Nerve Stim For Headaches; Cataract Removal

Enrollment in CardioFocus’ U.S. pivotal trial of the HeartLight endoscopic atrial fibrillation ablation system is complete. A small study shows that small wires implanted in the head may cure chronic headaches. Biolase and Auris announce plans to build a cataract removal robot.

New AF Ablation Tools Offer Promise Of Greater Efficacy, Durability

Novel arrhythmia mapping technologies, once they are clinically proven and validated, could change practice paradigms in the atrial fibrillation ablation space but in the meantime work continues on nearer-term advances that could make AF ablation more effective and durable. Three of the most promising – contact force sensing, endoscopic laser ablation, and atrial fibrosis imaging, from such companies as Endosense, Biosense Webster, CardioFocus, and Marrek – have recently achieved some important milestones in their journeys toward US market approval.

Device Companies Follow New Map To Atrial Fibrillation

Device therapies for atrial fibrillation (AF) have so far failed to result in compelling efficacy across all types of disease and patients. The rates of elimination of AF following a catheter ablation procedure range from 30% to 80% according to the type of patient and the definition of success. The question of why success rates aren’t yet sufficient after a great deal of investment is an area of active pursuit, and one that opens up the door for next-generation AF device companies seeking to improve upon the results achieved to date.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel